News & Presentations

SEATTLE, June 30, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.

SEATTLE, June 16, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have a poster presentation at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, to be held June 15-18, 2022 in San Francisco, California.

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France, June 10, 2022 – Umoja Biopharma, Inc.,…

SEATTLE and DALLAS, May 23, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, and Lupagen, Inc., a gene therapy company developing first-in-class gene delivery technologies for CAR-T, gene editing and immunotherapy products, today announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology.

SEATTLE, May 19, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced data from three presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on its scalable, off-the-shelf in vivo lentiviral vector-based platform, termed VivoVec, that has the potential to achieve efficient T cell transduction upon direct administration to patients.